181 related articles for article (PubMed ID: 38055116)
1. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.
Wang Z; Pan B; Su L; Yu H; Wu X; Yao Y; Zhang X; Qiu J; Tang N
Cell Oncol (Dordr); 2024 Apr; 47(2):513-532. PubMed ID: 38055116
[TBL] [Abstract][Full Text] [Related]
2. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
[TBL] [Abstract][Full Text] [Related]
3. Stigmasterol: Remodeling gut microbiota and suppressing tumor growth through Treg and CD8+ T cells in hepatocellular carcinoma.
Huo R; Yang WJ; Liu Y; Liu T; Li T; Wang CY; Pan BS; Wang BL; Guo W
Phytomedicine; 2024 Jul; 129():155225. PubMed ID: 38678948
[TBL] [Abstract][Full Text] [Related]
4. STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment.
Ao F; Li X; Tan Y; Jiang Z; Yang F; Guo J; Zhu Q; Chen Z; Zhou B; Zhang K; Li D
J Control Release; 2024 May; 369():296-308. PubMed ID: 38301925
[TBL] [Abstract][Full Text] [Related]
5. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
[TBL] [Abstract][Full Text] [Related]
6. Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation.
Ning J; Ye Y; Shen H; Zhang R; Li H; Song T; Zhang R; Liu P; Chen G; Wang H; Zang F; Li X; Yu J
Cell Rep Med; 2024 May; 5(5):101505. PubMed ID: 38614095
[TBL] [Abstract][Full Text] [Related]
7. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
Barsch M; Salié H; Schlaak AE; Zhang Z; Hess M; Mayer LS; Tauber C; Otto-Mora P; Ohtani T; Nilsson T; Wischer L; Winkler F; Manne S; Rech A; Schmitt-Graeff A; Bronsert P; Hofmann M; Neumann-Haefelin C; Boettler T; Fichtner-Feigl S; van Boemmel F; Berg T; Rimassa L; Di Tommaso L; Saeed A; D'Alessio A; Pinato DJ; Bettinger D; Binder H; John Wherry E; Schultheiss M; Thimme R; Bengsch B
J Hepatol; 2022 Aug; 77(2):397-409. PubMed ID: 35367533
[TBL] [Abstract][Full Text] [Related]
8. CD38 marks the exhausted CD8
Reolo MJY; Otsuka M; Seow JJW; Lee J; Lee YH; Nguyen PHD; Lim CJ; Wasser M; Chua C; Lim TKH; Leow WQ; Chung A; Goh BKP; Chow PKH; DasGupta R; Yeong JPS; Chew V
Front Immunol; 2023; 14():1182016. PubMed ID: 37377962
[TBL] [Abstract][Full Text] [Related]
9. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
Xiong Z; Chan SL; Zhou J; Vong JSL; Kwong TT; Zeng X; Wu H; Cao J; Tu Y; Feng Y; Yang W; Wong PP; Si-Tou WW; Liu X; Wang J; Tang W; Liang Z; Lu J; Li KM; Low JT; Chan MW; Leung HHW; Chan AWH; To KF; Yip KY; Lo YMD; Sung JJ; Cheng AS
Gut; 2023 Sep; 72(9):1758-1773. PubMed ID: 37019619
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
11. Effects of 3-HAA on HCC by Regulating the Heterogeneous Macrophages-A scRNA-Seq Analysis.
Xue C; Gu X; Zheng Q; Shi Q; Yuan X; Chu Q; Jia J; Su Y; Bao Z; Lu J; Li L
Adv Sci (Weinh); 2023 Jun; 10(16):e2207074. PubMed ID: 37013458
[TBL] [Abstract][Full Text] [Related]
12. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
13. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin.
Ruf B; Bruhns M; Babaei S; Kedei N; Ma L; Revsine M; Benmebarek MR; Ma C; Heinrich B; Subramanyam V; Qi J; Wabitsch S; Green BL; Bauer KC; Myojin Y; Greten LT; McCallen JD; Huang P; Trehan R; Wang X; Nur A; Murphy Soika DQ; Pouzolles M; Evans CN; Chari R; Kleiner DE; Telford W; Dadkhah K; Ruchinskas A; Stovroff MK; Kang J; Oza K; Ruchirawat M; Kroemer A; Wang XW; Claassen M; Korangy F; Greten TF
Cell; 2023 Aug; 186(17):3686-3705.e32. PubMed ID: 37595566
[TBL] [Abstract][Full Text] [Related]
15. Single-cell RNA sequencing highlights the role of PVR/PVRL2 in the immunosuppressive tumour microenvironment in hepatocellular carcinoma.
Li A; Ji B; Yang Y; Ye B; Zhu Q; Hu X; Liu Y; Zhou P; Liu J; Gao R; Zhou Q; Kang B; Jiang Y
Front Immunol; 2023; 14():1164448. PubMed ID: 37383234
[TBL] [Abstract][Full Text] [Related]
16. Knocking down of Xkr8 enhances chemotherapy efficacy through modulating tumor immune microenvironment.
Chen Y; Chen CY; Huang H; Luo Z; Mu Y; Li S; Huang Y; Li S
J Control Release; 2024 Jun; 370():479-489. PubMed ID: 38685385
[TBL] [Abstract][Full Text] [Related]
17. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
18. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
[TBL] [Abstract][Full Text] [Related]
19. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
20. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
